Recent research reveals a stark mismatch in U.S. Federal cancer research funding, where the deadliest cancers—including pancreatic, liver, and lung—receive disproportionately low investment relative to their mortality burden, despite accounting for nearly half of all cancer deaths. This imbalance, documented in a 2025 study published in JNCI Cancer Spectrum, persists even as advances in immunotherapy and early detection indicate promise for other malignancies, raising urgent questions about resource allocation and equity in oncology innovation.
Why Funding Disparities Matter for Patient Survival
The study found that while breast and prostate cancers receive the highest per-death federal funding, lethal cancers like pancreatic ductal adenocarcinoma (PDAC) and hepatocellular carcinoma (HCC) are severely underfunded despite their aggressive biology and limited treatment options. For example, pancreatic cancer accounts for approximately 8% of all cancer deaths but receives less than 3% of the National Cancer Institute’s (NCI) annual budget. This gap directly impacts clinical trial availability, biomarker development, and access to emerging therapies—particularly in underserved communities where late-stage diagnosis is more common. As survival gains stall for these high-mortality cancers, the funding imbalance threatens to widen existing disparities in cancer outcomes across racial, geographic, and socioeconomic lines.
In Plain English: The Clinical Takeaway
- Deadly cancers like pancreatic and liver cancer get far less research funding per death than more survivable cancers, slowing progress on new treatments.
- This funding gap means fewer clinical trials, delayed FDA approvals, and limited access to cutting-edge therapies—especially in rural and low-income areas.
- Patients should ask their oncologists about biomarker testing and trial eligibility, as early molecular profiling can unlock targeted options even in aggressive cancers.
Clinical Reality: Where the Science Stands Today
Pancreatic cancer, with a 5-year relative survival rate of just 13%, remains one of the most lethal malignancies due to its late presentation, dense stromal microenvironment, and resistance to chemotherapy. Mechanistically, PDAC is driven by KRAS mutations in over 90% of cases—a long-undruggable target until recent breakthroughs with covalent inhibitors like sotorasib (approved for lung cancer) showed early promise in pancreatic trials. Similarly, hepatocellular carcinoma often arises in the context of chronic hepatitis B or C infection or non-alcoholic fatty liver disease (NAFLD), with tumor progression fueled by vascular endothelial growth factor (VEGF) and immune checkpoint dysregulation. While immune-based therapies like atezolizumab plus bevacizumab have improved first-line survival in HCC, response rates remain modest, and secondary resistance is common.
Lung cancer, though benefiting from dramatic advances in EGFR and ALK-targeted therapies and immunotherapy, still sees unequal outcomes: Black patients are 15% less likely to receive surgical intervention for early-stage non-small cell lung cancer (NSCLC) compared to White patients, according to a 2024 CDC analysis, and rural hospitals often lack access to comprehensive genomic profiling or multidisciplinary tumor boards.
Geo-Epidemiological Bridging: Access Divides in Cancer Care
These funding and biological challenges translate directly into regional disparities in care. In states with Medicaid expansion under the Affordable Care Act, early-stage lung cancer detection via low-dose CT screening has increased by 22% since 2020, per NIH data—but in non-expansion states, screening rates remain below 8%. Similarly, liver cancer incidence is rising fastest among Hispanic and Asian/Pacific Islander populations, yet access to hepatitis B vaccination and antiviral therapy—key preventive measures—varies widely by state Medicaid policies and community health center funding. The FDA’s accelerated approval pathway has helped bring drugs like pembrolizumab to microsatellite instability-high (MSI-H) cancers regardless of origin, but biomarker testing rates lag in safety-net hospitals, where pathology departments may lack next-generation sequencing (NGS) capabilities.
Internationally, the contrast is stark: the UK’s NHS Genomic Medicine Service offers whole-genome sequencing to all cancer patients at diagnosis, while the EMA’s adaptive licensing model accelerates access to breakthrough therapies. In the U.S., patchwork insurance coverage and prior authorization delays often mean that even FDA-approved treatments reach patients weeks or months later than in comparable high-income nations.
Funding Sources and Research Integrity
The 2025 study analyzing federal cancer funding disparities was conducted by researchers at the Harvard T.H. Chan School of Public Health and funded entirely by the National Institutes of Health (NIH) through grant R01-CA268421. No industry support was reported, and the authors declared no conflicts of interest. The analysis used publicly available NCI budget data, SEER mortality statistics, and congressional appropriations reports from 2015 to 2022, ensuring transparency and reproducibility.
“When we fund cancer research based on advocacy visibility rather than biological urgency, we inadvertently penalize patients with the least survivable diseases. This isn’t just a budgeting issue—it’s a matter of scientific equity.”
— Dr. Elena Rodriguez, PhD, Lead Epidemiologist, Harvard T.H. Chan School of Public Health, speaking at the 2025 American Association for Cancer Research (AACR) Annual Meeting.
“We demand to shift from funding cancers that are loud to funding those that are lethal. Pancreatic and liver cancers don’t have marches or celebrity champions—but they kill more Americans each year than breast and prostate cancer combined.”
— Dr. James K. Lee, MD, Director of Hepatobiliary Oncology, Mayo Clinic, in testimony before the Senate Appropriations Subcommittee on Labor, Health and Human Services, March 2026.
Data Snapshot: Federal Funding vs. Mortality Burden by Cancer Type (2022)
| Cancer Type | % of U.S. Cancer Deaths | % of NCI Budget | Funding per Death (Relative Index) |
|---|---|---|---|
| Breast | 14% | 22% | 1.57 |
| Prostate | 11% | 18% | 1.64 |
| Lung & Bronchus | 21% | 13% | 0.62 |
| Colorectal | 9% | 10% | 1.11 |
| Pancreatic | 8% | 3% | 0.38 |
| Liver & Intrahepatic Bile Duct | 5% | 2% | 0.40 |
Source: NCI Fact Book 2022, SEER Cancer Statistics Review 1975-2020. Relative Index = (% NCI Budget / % Cancer Deaths). Values >1.0 indicate funding above mortality burden.
Contraindications & When to Consult a Doctor
This analysis does not describe a treatment or intervention, so traditional contraindications do not apply. However, individuals with a family history of pancreatic, liver, or lung cancer should consult a genetic counselor about hereditary risk syndromes (e.g., BRCA2, Lynch syndrome, HFE-related hemochromatosis). Anyone experiencing unexplained weight loss, jaundice, new-onset diabetes after age 50, or persistent abdominal or back pain should seek prompt medical evaluation—these can be early signs of lethal malignancies. Early detection remains critical: for pancreatic cancer, survival increases from 3% to over 30% when diagnosed at Stage I, underscoring the value of vigilance in high-risk populations.
Patients currently undergoing cancer therapy should discuss clinical trial eligibility with their oncologist, particularly if standard options have been exhausted. Resources like ClinicalTrials.gov and the NIH’s Cancer Information Service (1-800-4-CANCER) can help identify location- and biomarker-matched studies.
The Path Forward: Toward Equitable Investment in Cancer Science
Closing the funding gap requires deliberate policy action: Congress could direct the NCI to adopt a mortality-weighted funding model, as advocated by the American Association for Cancer Research. Simultaneously, expanding access to biomarker testing through CMS coverage reforms and investing in community-based oncology navigation programs could ensure that scientific advances reach those most in need. Promising developments—such as mRNA vaccines targeting pancreatic cancer neoantigens (currently in Phase I trials at Moderna and BioNTech) and T-cell engagers for hepatocellular carcinoma—demonstrate that scientific ingenuity exists; what’s missing is the sustained, equitable investment to bring these innovations from bench to bedside.
Until then, the stark reality remains: in the war against cancer, the deadliest enemies are often the least resourced. Correcting this imbalance isn’t just scientifically sound—it’s a moral imperative for a healthcare system that claims to abandon no one behind.
References
- Liang PS, et al. Federal funding for cancer research in relation to mortality burden. JNCI Cancer Spectrum. 2025;9(4):pkab045. Doi:10.1093/jncics/pkab045.
- Howlader N, et al. SEER Cancer Statistics Review, 1975-2020. National Cancer Institute. Bethesda, MD, 2023.
- National Cancer Institute. NCI Fact Book 2022. NIH Publication No. 22-ca-8105. Bethesda, MD.
- American Cancer Society. Cancer Facts & Figures 2026. Atlanta: American Cancer Society; 2026.
- Centers for Disease Control and Prevention. Cancer Prevention and Control. Updated March 2026. Https://www.cdc.gov/cancer.
